Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6605
pubmed:dateCreated
1988-1-29
pubmed:abstractText
Fourteen patients with uraemic anaemia and having regular haemodialysis were given human recombinant erythropoietin in increasing doses, beginning with 24 U/kg thrice weekly. One patient was dropped from the study because of recurrent thrombosis of vascular access sites. In the other 13 patients, followed up for a mean of 9.1 months (range 8-11), haemoglobin concentrations increased from 62 (SD 8) to 105 (9) g/l. No antierythropoietin antibodies were detected during the study. The correction of anaemia was associated with a tendency to hyperkalaemia and a mild increase of unconjugated bilirubinaemia. In eight previously hypertensive patients antihypertensive treatment had to be reinforced, but in normotensive patients blood pressure did not change. Thrombosis of arteriovenous fistulas occurred in two patients and a cerebral ischaemic lesion in one. Protracted treatment with human recombinant erythropoietin evidently can maintain normal haemoglobin concentrations in uraemic patients over time. Full correction of anaemia, however, may trigger some vascular problems, particularly in hypertensive patients and those with a tendency to thromboembolism.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-2877323, http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-3584994, http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-3838366, http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-3865178, http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-4133418, http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-4869104, http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-4931294, http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-5059128, http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-6127502, http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-688606, http://linkedlifedata.com/resource/pubmed/commentcorrection/3120854-7058145
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0267-0623
pubmed:author
pubmed:issnType
Print
pubmed:day
24
pubmed:volume
295
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1017-20
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.
pubmed:affiliation
Divisione di Nefrologia, Ospedale Maggiore Policlinico, Milan, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't